1. |
Honda M, Sugawara Y, Kadohisa M, et al. Long-term outcomes of ABO-incompatible pediatric living donor liver transplantation. Transplantation, 2018, 102(10): 1702-1709.
|
2. |
Crins ND, Röver C, Goralczyk AD, et al. Interleukin-2 receptor antagonists for pediatric liver transplant recipients: A systematic review and meta-analysis of controlled studies. Pediatr Transplant, 2014, 18(8): 839-850.
|
3. |
Ganschow R, Grabhorn E, Schulz A, et al. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. Pediatr Transplant, 2005, 9(6): 741-745.
|
4. |
Newland DM, Royston MJ, McDonald DR, et al. Analysis of rabbit anti-thymocyte globulin vs basiliximab induction in pediatric liver transplant recipients. Pediatr Transplant, 2019, 23(8): e13573.
|
5. |
Sun C, Song Z, Ma N, et al. The management and outcomes of ABO-incompatible pediatric liver transplantation: Experience of a single Chinese center. J Pediatr Surg, 2020, 55(12): 2647-2652.
|
6. |
高卓, 王旖旎. EB病毒DNA检测应尽早实现标准化. 中华传染病杂志, 2017, 35(5): 318-320.
|
7. |
Lee B, Choi Y, Han HS, et al. ABO-incompatible liver transplantation using only rituximab for patients with low anti-ABO antibody titer. Ann Hepatobiliary Pancreat Surg, 2019, 23(3): 211-218.
|
8. |
Bajpai M, Kakkar B, Gupta S, et al. Cascade plasmapheresis as a desensitization strategy for patients undergoing ABO incompatible living donor liver transplantation (ABOi LDLT): A single center experience. Transfus Apher Sci, 2019, 58(4): 442-446.
|
9. |
Mysore KR, Himes RW, Rana A, et al. ABO-incompatible deceased donor pediatric liver transplantation: Novel titer-based management protocol and outcomes. Pediatr Transplant, 2018, 22(7): e13263.
|
10. |
Ueda D, Yoshizawa A, Kaneshiro M, et al. Low titers of antidonor ABO antibodies after ABO-incompatible living donor liver transplantation: A long-term follow-up study. Transplant Direct, 2018, 5(1): e420.
|
11. |
Kim SH, Park J, Park SJ. Impact of ABO-incompatibility on hepatic artery thrombosis in living donor liver transplantation. Ann Transl Med, 2019, 7(22): 625.
|
12. |
Oh J, Kim JM. Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation. Clin Mol Hepatol, 2020, 26(1): 1-6.
|
13. |
Egawa H. Challenge to ABO blood type barrier in living donor liver transplantation. Hepatobiliary Pancreat Dis Int, 2020, 19(4): 342-348.
|
14. |
Di Filippo S. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. Pediatr Transplant, 2005, 9(3): 373-380.
|
15. |
Turner AP, Knechtle SJ. Induction immunosuppression in liver transplantation: a review. Transpl Int, 2013, 26(7): 673-683.
|
16. |
Ganschow R, Broering DC, Stuerenburg I, et al. First experience with basiliximab in pediatric liver graft recipients. Pediatr Transplant, 2001, 5(5): 353-358.
|
17. |
陈凡, 高伟, 孙超, 等. 巴利昔单抗对儿童肝移植受者的有效性及安全性评价. 中华小儿外科杂志, 2017, 38(1): 42-45.
|
18. |
Mouzaki M, Yap J, Avinashi V, et al. Basiliximab with delayed introduction of calcineurin inhibitors as a renal-sparing protocol following liver transplantation in children with renal impairment. Pediatr Transplant, 2013, 17(8): 751-756.
|
19. |
Spada M, Petz W, Bertani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant, 2006, 6(8): 1913-1921.
|
20. |
Tokodai K, Miyagi S, Nakanishi C, et al. Association of post-transplant donor-specific HLA antibody with liver graft fibrosis during long-term follow-up after pediatric liver transplantation. Pediatr Transplant, 2018, 22(3): e13169.
|
21. |
孙超, 孟醒初, 董冲, 等. 小儿血型不合活体肝移植的临床疗效分析. 器官移植, 2020, 11(4): 466-470.
|